Publications by authors named "R J Latour"
Climate change is shifting the timing of organismal life-history events. Although consequential food-web mismatches can emerge if predators and prey shift at different rates, research on phenological shifts has traditionally focused on single trophic levels. Here, we analysed >2000 long-term, monthly time series of phytoplankton, zooplankton, and fish abundance or biomass for the San Francisco, Chesapeake, and Massachusetts bays.
View Article and Find Full Text PDFArticle Synopsis
- Prophylaxis strategies for Graft versus Host Disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT) often include a calcineurin inhibitor (CNI) combined with either methotrexate (MTX) or mycophenolate mofetil (MMF).
- A study analyzing data from 13,699 patients revealed that MTX-based prophylaxis was linked to lower overall mortality and non-relapse mortality compared to MMF, while showing no significant impact on relapse rates or relapse-free survival.
- Overall, MTX in combination with CNI was associated with better survival outcomes and a lower risk of severe acute GVHD compared to MMF.
Practical steps to green your endoscopy unit: appropriate management of endoscopic waste.
Gastrointest Endosc
October 2024
Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Am J Hematol
July 2024
In the context of T-cell replete haploidentical stem cell transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy), it is still unknown whether peripheral blood (PB) or bone marrow (BM) is the best graft source. While PB is associated with a higher incidence of graft-versus-host disease (GVHD), it may induce a stronger graft-versus-leukemia effect compared to BM, notably in acute myeloid leukemia (AML). From the EBMT registry database, we compared T-cell replete PB (n = 595) versus BM (n = 209) grafts in a large cohort of 804 patients over the age of 60 years who underwent Haplo-SCT with PT-Cy for an AML in first or second complete remission.
View Article and Find Full Text PDFIntroduction: Pegcetacoplan, the first approved proximal complement C3 inhibitor, showed superiority to eculizumab in improving hemoglobin levels and clinical outcomes in the phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH) and inadequate response to eculizumab.
Methods: This analysis evaluates the efficacy and safety of pegcetacoplan for Japanese patients in PEGASUS, as they are known for different clinicopathologic features compared to non-Asian patients. Ten Japanese patients were enrolled to receive pegcetacoplan (n=5) or eculizumab (n=5) during the 16-week randomized controlled period.